Erasca Shares Plunge 53.9% Following Class Action Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Source: PRnewswire
- Stock Price Collapse: Erasca's shares plummeted from $21.49 on April 24, 2026, to $9.90 by April 28, resulting in an $11.59 per share loss and a 53.9% decline, indicating a severe erosion of market confidence in the company's prospects.
- Class Action Lawsuit: Levi & Korsinsky LLP has alerted investors about a pending class action aimed at recovering damages for those who purchased Erasca securities between January 14, 2025, and April 26, 2026, highlighting significant investor concerns regarding the company's disclosure practices.
- Disclosure Issues: The two corrective disclosures on April 27 and 28 revealed patent infringement allegations and a patient death in clinical trials, exposing misleading comparisons made by the company regarding ERAS-0015, which exacerbated investor losses.
- Investor Compensation Opportunities: Investors have until August 10, 2026, to apply for lead plaintiff status, and even those who do not apply can still participate in any recovery, indicating that the company's legal challenges may impact its future capital market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging the company failed to disclose critical adverse facts that may have led to investor losses.
- False Statements Allegations: The lawsuit claims that Erasca made false and misleading statements regarding the preclinical data of ERAS-0015, asserting that improper comparisons to Revolution Medicines placed the company at risk of patent and trade secret violations, misleading investors about the drug's prospects.
- Stock Price Plummet: Following the disclosure on April 28, 2026, that Erasca received a letter from Revolution Medicines alleging patent infringement related to ERAS-0015, the stock price plummeted from $19.15 to $9.90, a decline of approximately 48%, significantly impacting investor confidence.
- Investor Action Encouraged: Affected investors are urged to apply by August 10, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost consultations to help investors understand their rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Via Transportation Class Action: From September 2025 to June 2026, Via Transportation is accused of failing to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about the company's prospects and potentially hindering its expansion strategy in Germany.
- Zillow Class Action: During the period from February 2025 to May 2026, Zillow allegedly failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, increasing its exposure to antitrust legal risks, which could negatively impact the company's reputation and stock price.
- ADMA Biologics Class Action: From August 2024 to March 2026, ADMA is accused of engaging in undisclosed related party transactions and channel stuffing, leading to distorted financial reporting that could undermine investor confidence and future financing capabilities.
- Erasca Class Action: Between January 2025 and April 2026, Erasca is alleged to have failed to disclose improper comparisons in its preclinical data, risking violations of patent and trade secret protections, which could affect the company's future R&D and market competitiveness.
See More
Erasca Shares Plunge 53.9% Following Class Action Announcement
- Stock Price Collapse: Erasca's shares plummeted from $21.49 on April 24, 2026, to $9.90 by April 28, resulting in an $11.59 per share loss and a 53.9% decline, indicating a severe erosion of market confidence in the company's prospects.
- Class Action Lawsuit: Levi & Korsinsky LLP has alerted investors about a pending class action aimed at recovering damages for those who purchased Erasca securities between January 14, 2025, and April 26, 2026, highlighting significant investor concerns regarding the company's disclosure practices.
- Disclosure Issues: The two corrective disclosures on April 27 and 28 revealed patent infringement allegations and a patient death in clinical trials, exposing misleading comparisons made by the company regarding ERAS-0015, which exacerbated investor losses.
- Investor Compensation Opportunities: Investors have until August 10, 2026, to apply for lead plaintiff status, and even those who do not apply can still participate in any recovery, indicating that the company's legal challenges may impact its future capital market performance.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
Erasca Inc. Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information and choose qualified legal counsel to ensure their rights are effectively protected.
See More
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging the company failed to disclose critical adverse facts that may have led to investor losses.
- False Statements Allegations: The lawsuit claims that Erasca made false and misleading statements regarding the preclinical data of ERAS-0015, asserting that improper comparisons to Revolution Medicines placed the company at risk of patent and trade secret violations, misleading investors about the drug's prospects.
- Stock Price Plummet: Following the disclosure on April 28, 2026, that Erasca received a letter from Revolution Medicines alleging patent infringement related to ERAS-0015, the stock price plummeted from $19.15 to $9.90, a decline of approximately 48%, significantly impacting investor confidence.
- Investor Action Encouraged: Affected investors are urged to apply by August 10, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost consultations to help investors understand their rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Via Transportation Class Action: From September 2025 to June 2026, Via Transportation is accused of failing to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about the company's prospects and potentially hindering its expansion strategy in Germany.
- Zillow Class Action: During the period from February 2025 to May 2026, Zillow allegedly failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, increasing its exposure to antitrust legal risks, which could negatively impact the company's reputation and stock price.
- ADMA Biologics Class Action: From August 2024 to March 2026, ADMA is accused of engaging in undisclosed related party transactions and channel stuffing, leading to distorted financial reporting that could undermine investor confidence and future financing capabilities.
- Erasca Class Action: Between January 2025 and April 2026, Erasca is alleged to have failed to disclose improper comparisons in its preclinical data, risking violations of patent and trade secret protections, which could affect the company's future R&D and market competitiveness.
See More
Erasca Shares Plunge 53.9% Following Class Action Announcement
- Stock Price Collapse: Erasca's shares plummeted from $21.49 on April 24, 2026, to $9.90 by April 28, resulting in an $11.59 per share loss and a 53.9% decline, indicating a severe erosion of market confidence in the company's prospects.
- Class Action Lawsuit: Levi & Korsinsky LLP has alerted investors about a pending class action aimed at recovering damages for those who purchased Erasca securities between January 14, 2025, and April 26, 2026, highlighting significant investor concerns regarding the company's disclosure practices.
- Disclosure Issues: The two corrective disclosures on April 27 and 28 revealed patent infringement allegations and a patient death in clinical trials, exposing misleading comparisons made by the company regarding ERAS-0015, which exacerbated investor losses.
- Investor Compensation Opportunities: Investors have until August 10, 2026, to apply for lead plaintiff status, and even those who do not apply can still participate in any recovery, indicating that the company's legal challenges may impact its future capital market performance.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
Erasca Inc. Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information and choose qualified legal counsel to ensure their rights are effectively protected.
See More
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
